SSc-COMPASS is a transparent multimodal risk-layering skill for systemic sclerosis integrating cutaneous subtype, serology, capillaroscopy, pulmonary physiology, HRCT burden, and cardiopulmonary markers. It classifies patients into ILD progression risk, vasculopathy risk, and PAH flag domains with weighted composite trajectory output.
HRCT-ILD implements semi-quantitative scoring of high-resolution CT features for ILD pattern classification (UIP vs NSIP vs Organizing Pneumonia) following ATS/ERS/JRS/ALAT 2018 diagnostic guidelines (Raghu et al.).
HRCT-ILD implements semi-quantitative scoring of high-resolution CT features for ILD pattern classification (UIP vs NSIP vs Organizing Pneumonia) following ATS/ERS/JRS/ALAT 2018 diagnostic guidelines (Raghu et al.).
ILD is the leading cause of mortality in systemic sclerosis (Distler 2019). ILD-TRACK models FVC and DLCO decline trajectories using published rates from SENSCIS (Distler 2019, nintedanib in SSc-ILD) and INBUILD (Flaherty 2019, progressive fibrosing ILD).
Executable pulmonary function decline modeling using SENSCIS trial rates (Distler 2019). Monte Carlo projections.
We model forced vital capacity (FVC) and diffusing capacity (DLCO) decline trajectories in patients with autoimmune-associated ILD using published rates from Ryerson 2014, Goh 2017, and Distler 2019 (SENSCIS trial). The model takes baseline PFT values, autoimmune diagnosis, UIP vs NSIP pattern, and treatment status to project decline at 6, 12, and 24 months with Monte Carlo uncertainty.
Interstitial lung disease (ILD) is the leading cause of mortality in systemic sclerosis, dermatomyositis, and RA-ILD. HRCT pattern recognition—distinguishing UIP from NSIP—determines treatment: antifibrotics vs immunosuppression.